Smoking increases the risk of cardiovascular events when combined with estrogen-containing contraceptives. Women who smoke ≥ 15 cigarettes per day and are aged ≥ 35 years should avoid Diane 35 and consider non-hormonal or progestogen-only methods.
Visible improvement in acne typically begins after 4-6 weeks of consistent use, though the full therapeutic effect may require up to 3 months.
Most antibiotics (e.g., amoxicillin, doxycycline) do not affect contraceptive efficacy. However, rifampicin and other strong CYP3A4 inducers can reduce hormone levels; a backup method is recommended during and for 28 days after such antibiotics.
Yes, Diane 35 can be carried in personal luggage. Keep the original packaging and a copy of the prescription to facilitate customs checks, especially when traveling to countries with strict medication import regulations.
Severe or sudden headaches, especially with visual disturbances, may signal a serious vascular event. Seek immediate medical attention and discontinue the pill until evaluated.
Combined oral contraceptives can alter serum hormone measurements (e.g., estradiol, testosterone). Inform the laboratory of contraceptive use to ensure appropriate interpretation of results.
No specific foods need to be avoided. Maintaining a balanced diet supports overall health, but excessive grapefruit intake may interfere with some drug metabolism pathways, although the effect on Diane 35 is minimal.
No. Diane 35 is not indicated for emergency contraception. If unprotected intercourse occurs, a dedicated emergency contraceptive pill (e.g., levonorgestrel) should be used within 72 hours.
Generic versions containing the same combination of cyproterone acetate 2 mg and ethinylestradiol 0.035 mg are marketed under different brand names. The clinical profile remains equivalent when prescribed by a qualified prescriber.
Diane 35 is a combined oral contraceptive pill that contains cyproterone acetate 2 mg and ethinylestradiol 0.035 mg per tablet. It belongs to the women’s health therapeutic group and is marketed in the United Kingdom under the brand name Diane 35. The product is prescription-only (POM) and is regulated by the Medicines and Healthcare products Regulatory Agency (MHRA). Diane 35 is supplied as a round white tablet intended for oral administration.
Diane 35 combines two hormonal agents that act on the hypothalamic-pituitary-gonadal axis:
Together, these agents provide reliable contraception while also addressing androgen-related skin conditions. Onset of contraceptive protection occurs after the first tablet if taken correctly; the anti-androgenic benefits of cyproterone acetate typically become noticeable after several weeks of continuous use.
In the United Kingdom, Diane 35 is licensed for two primary indications:
Both indications are supported by the product’s Summary of Product Characteristics (SPC) and the British National Formulary (BNF). Diane 35 is not listed for the management of other dermatological or endocrine disorders.
Clinical studies have explored the use of cyproterone acetate/ethinylestradiol combinations for conditions such as polycystic ovary syndrome (PCOS)-related hyperandrogenism and female pattern hair loss. While some evidence suggests benefit, these uses are not approved by the MHRA for Diane 35. Physicians may consider them only after a thorough risk-benefit assessment and with informed consent.
Off-label disclaimer: Off-label use requires supervision by a qualified healthcare professional and individualized risk assessment.
Major interactions
Strong CYP3A4 inducers (rifampicin, carbamazepine, St John’s wort) → reduced contraceptive efficacy; alternative non-hormonal contraception advised.
Antifungals (ketoconazole, itraconazole) → may increase plasma concentrations of ethinylestradiol; monitor for estrogen-related side effects.
Moderate interactions
Antidepressants (SSRIs, SNRIs) → may increase the risk of bleeding when combined with NSAIDs.
Lithium → combined use may increase lithium levels; monitor serum lithium.
General advice: Patients should disclose all prescription medicines, over-the-counter products, herbal supplements, and vitamins to their prescriber before starting Diane 35.
This article provides educational information about Diane 35 and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
